moatshark My

All holdings

Sophia Genetics

SOPH

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$21.5m
Combined value at quarter end
Last quarter
0 bought
0 sold or trimmed
Price at Q2 ’26 end
$5.77
+16.6% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-20.3%Q3 ’24
-15.9%Q4 ’24
+8.1%Q1 ’25
-6.6%Q2 ’25
+53.5%Q3 ’25
-1.9%Q4 ’25
+6.0%Q1 ’26
+16.6%Q2 ’26
Q3 ’24: -20.3%; Q4 ’24: -15.9%; Q1 ’25: +8.1%; Q2 ’25: -6.6%; Q3 ’25: +53.5%; Q4 ’25: -1.9%; Q1 ’26: +6.0%; Q2 ’26: +16.6%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
2Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 2; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Sophia Genetics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Sophia Genetics
Akre Capital Management0.4%$21.5m$21.5mUnchanged10 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Sophia Genetics
Bought or soldFiling
13 Oct 2026Xu ZhenyuChief Scientific Officer▼ Sold4,000$7.18$29kForm 4
12 Oct 2026Camblong JurgiExecutive Chairman▼ Sold8,500$7.26$62kForm 4
12 Oct 2026Menu PhilippeChief Medical Officer▼ Sold5,000$7.26$36kForm 4
5 Oct 2026Camblong JurgiExecutive Chairman▼ Sold40,172$8.13$327kForm 4
5 Oct 2026Muken RossChief Executive Officer▼ Sold9,838$8.13$80kForm 4
5 Oct 2026Menu PhilippeChief Medical Officer▼ Sold7,394$8.13$60kForm 4
5 Oct 2026Xu ZhenyuChief Scientific Officer▼ Sold7,394$8.12$60kForm 4
5 Oct 2026Van Well DaanChief Legal Officer▼ Sold6,168$8.12$50kForm 4
5 Oct 2026Verma AbhimanyuChief Technology Officer▼ Sold5,284$8.12$43kForm 4
5 Oct 2026Valente ManuelaChief People Officer▼ Sold4,240$8.13$34kForm 4
5 Oct 2026Cardoza GeorgeChief Financial Officer▼ Sold1,592$8.10$13kForm 4
5 Oct 2026Puylaert KevinChief Sales Officer▼ Sold185$8.06$1kForm 4
5 Oct 2026Puylaert KevinChief Sales Officer▼ Sold31$7.92$0kForm 4
21 Sep 2026Cardoza GeorgeChief Financial Officer▼ Sold774$8.33$6kForm 4
21 Sep 2026Muken RossChief Executive Officer▼ Sold422$8.33$4kForm 4
14 Sep 2026Menu PhilippeChief Medical Officer▼ Sold5,000$7.88$39kForm 4
14 Sep 2026Xu ZhenyuChief Scientific Officer▼ Sold4,000$7.88$32kForm 4
11 Sep 2026Van Well DaanChief Legal Officer▼ Sold6,168$7.63$47kForm 4
10 Sep 2026Camblong JurgiExecutive Chairman▼ Sold8,500$7.66$65kForm 4
8 Sep 2026Hibbs Kathy LDirector▼ Sold6,250$8.13$51kForm 4

About the company

Sector
Technology · Services-Computer Processing & Data Preparation
Financial year ends
31 December
Shares outstanding
68m at 31 Dec 2025
SEC filings
Annual reports and other filings on EDGAR